A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.

Vaccine · 2023 · PMC9946892 · PMID 36842886

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

This manufacturing capacity is extremely significant and far surpasses the production throughput and costs of the other viral-based, nucleic acid-based, and full-length recombinant SP subunit-based vaccines.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.